Bain Capital Deal History & Licensing Activity
Bain Capital is a life sciences. Over the past three years, Bain Capital has been involved in 1 licensing and acquisition transaction, with a primary focus on Antibodies (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Antibodies
Focus Area
Neurology
Bain Capital Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Bain Capital in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Uplizna | Mitsubishi Tanabe Pharma | Antibodies | Approved | acquisition | Jul 2025 |
Bain Capital Pipeline Focus
Therapeutic areas and modalities where Bain Capital is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Bain Capital Strategic Signals
Key indicators of Bain Capital's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Bain Capital's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Bain Capital Licensing & Deal Activity
Bain Capital is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Bain Capital ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Bain Capital include Neurology (2 deals and trials). In terms of modality, Bain Capital has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bain Capital and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Bain Capital's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.